Literature DB >> 25327439

White coat effect and masked uncontrolled hypertension in treated hypertensive-diabetic patients: Prevalence and target organ damage.

Liana F Leiria1, Mateus D Severo2, Priscila S Ledur2, Alexandre D Becker2, Fernanda M Aguiar3, Daniela Massierer1, Valéria C Freitas1, Beatriz D Schaan2, Miguel Gus1.   

Abstract

BACKGROUND: The association between hypertensive phenotypes of controlled hypertension (CH), white-coat effect (WCE), masked uncontrolled hypertension (MUH) and sustained hypertension (SH) with target organ damage have not been clearly established in diabetic hypertensive treated patients. The present study aims to evaluate the prevalence of the four phenotypes considering the current cut-off points for office and 24 h-ambulatory blood pressure monitoring (ABPM) and the association with left ventricle hypertrophy (LVH), diastolic function and nephropathy.
METHODS: Cross-sectional study with 304 patients on anti-hypertensive treatment aged 57.6 ± 6.1 years, who were submitted to ABPM and echocardiography. They were classified into CH (normal office BP and ABPM), WCE (high office BP and normal ABPM), MUH (normal office BP and high ABPM), and SH (high office BP and ABPM).
RESULTS: Median HbA1c and diabetes duration were 7.9% (6.8-9.2), and 10 years (5-16), respectively. Prevalences of CH, WCE, MUH and SH were 27.3%, 17.1%, 18.8%, and 36.8%. MUH prevalence was higher than previously described. There was a significant increasing trend across the four groups in variables related to LVH (P < 0.001 for trend). There was not a clear "dose-response" relationship of the four hypertensive phenotypes with nephropathy and diastolic function.
CONCLUSION: The use of ABPM beyond the traditional cardiovascular risk stratification tools has limitations, but is still useful in high-risk patients. Longitudinal studies could better evaluate the role of the use of ABPM in this scenario. Cut-off points for normality of office and ABPM influence the prevalences of WCH and MUH.
© 2014 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  echocardiography; masked hypertension; type 2 diabetes mellitus; white-coat hypertension; 关键词:超声心动图,隐蔽性高血压,2型糖尿病,白大衣高血压

Mesh:

Substances:

Year:  2015        PMID: 25327439     DOI: 10.1111/1753-0407.12231

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  5 in total

1.  Masked uncontrolled hypertension in patients on maintenance hemodialysis.

Authors:  Wenjin Liu; Liang Wang; Zhuxing Sun; Xiurong Li; Jianmei Zhou; Chaoqing Gao; Hong Chu; Wei Fan; Youwei Bai; Junwei Yang
Journal:  Hypertens Res       Date:  2017-04-06       Impact factor: 3.872

2.  Evaluation of the applicability of deep breathing test in the diagnosis of hypertension with white-coat effect in Chinese patients in primary care.

Authors:  Kam Sum Chan; Kit Ping Loretta Lai; Pang Fai Chan; Man Hei Matthew Luk; Vai Kiong David Chao
Journal:  Clin Hypertens       Date:  2019-02-01

3.  Association between Systolic Blood Pressure and Diabetic Retinopathy in Both Hypertensive and Normotensive Patients with Type 2 Diabetes: Risk Factors and Healthcare Implications.

Authors:  Yu-Ting Li; Yi Wang; Xiu-Jing Hu; Jia-Heng Chen; Yun-Yi Li; Qi-Ya Zhong; Hui Cheng; Bedru H Mohammed; Xiao-Ling Liang; Jose Hernandez; Wen-Yong Huang; Harry H X Wang
Journal:  Healthcare (Basel)       Date:  2021-05-13

4.  Blood pressure variability and its association with echocardiographic parameters in hypertensive diabetic patients.

Authors:  Daniela Massierer; Liana Farias Leiria; Mateus Dorneles Severo; Priscila Dos Santos Ledur; Alexandre Dalpiaz Becker; Fernanda Mus Aguiar; Eliandra Lima; Valéria Centeno Freitas; Beatriz D Schaan; Miguel Gus
Journal:  BMC Cardiovasc Disord       Date:  2016-01-08       Impact factor: 2.298

Review 5.  Hypertension and metabolic disorders, a glance from different phenotypes.

Authors:  Daniel Piskorz
Journal:  Am J Prev Cardiol       Date:  2020-07-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.